<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309491</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG-6</org_study_id>
    <nct_id>NCT00309491</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients</brief_title>
  <official_title>A Randomized Phase III Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primarily, this clinical investigation compared the efficacy of tamoxifen + aminoglutethimide
      vs. tamoxifen alone in terms of prognosis (overall survival) in postmenopausal patients with
      potentially curative, operated hormone receptor-positive breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1990</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effect profiles</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2020</enrollment>
  <condition>Early-stage Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen + Aminoglutethimide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen alone</intervention_name>
    <description>2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen + Aminoglutethimide</intervention_name>
    <description>2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)
1st therapy week:125mg/-/125mg Aminoglutethimide daily
2nd therapy week: 125mg/-/250mg Aminoglutethimid daily
as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily</description>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Nolvadex + Orimeten</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal patients with histologically verified, locoradically treated, invasive
             or minimally invasive breast cancer

          -  Hormone receptor-positive status

          -  More than 6 histologically examined lymph nodes

          -  Laboratory parameters

               1. hematopoiesis: &gt; 3500/µl leucocytes, &gt; 100,000/µl thrombocytes

               2. renal function: creatinin &lt; 1.5mg%

               3. hepatic function: GOT &lt; 2.5 x UNL

               4. bilirubin: &lt; 1.5mg %

               5. metabolic parameters: Na, Ca, K in normal range, normal level of blood sugar

          -  Concluded healing process following surgery

          -  Less than 4 weeks interval since surgery

          -  Informed consent

        Exclusion Criteria:

          -  Premenopausal patients, non-determinable menopausal status

          -  Previous radiotherapy, chemotherapy or endocrine treatment

          -  Generalized disease (as verified by lung X-ray, skeletal X-ray, liver ultrasound)

          -  Contraindications against tamoxifen or anastrozole

          -  T4 tumors; carcinoma in situ

          -  Lacking compliance or understanding of disease

          -  Karnofsky Index &lt; 3

          -  Serious concomitant disease

          -  Septic complications, systemic infections or infectious local processes

          -  Bilateral ovariectomy or ovarian irradiation

          -  Second carcinoma or status post second carcinoma (except for treated squamous cell
             carcinoma of the skin or cervical carcinoma in situ)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raimund Jakesz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <link>
    <url>http://www.abcsg.at</url>
    <description>Click here for more information about this study: publications</description>
  </link>
  <reference>
    <citation>Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M; ABCSG. Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. Br J Cancer. 2013 Apr 16;108(7):1408-14. doi: 10.1038/bjc.2013.114. Epub 2013 Mar 19.</citation>
    <PMID>23511562</PMID>
  </reference>
  <reference>
    <citation>Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol. 2003 Mar 15;21(6):984-90.</citation>
    <PMID>12637461</PMID>
  </reference>
  <reference>
    <citation>Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M; Austrian Breast and Colorectal Cancer Study Group. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res. 2008 Mar 15;14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122.</citation>
    <PMID>18347178</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2016</last_update_posted>
  <keyword>Tamoxifen</keyword>
  <keyword>Aminoglutethimide</keyword>
  <keyword>Breast cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Aminoglutethimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

